Reading PEPG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PEPG free→Reading PEPG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PEPG free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, while management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, which may impact future performance. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $1.53. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.00x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.29 → $-0.29 (+1.1% / 30d). 3 raised, 1 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 86% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$306.
How much price usually moves either way.
On a bad day, this stock has moved -$948.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,117.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PEPG yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 12, 2026, PepGen Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other business updates and issued a press release titled “ PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights .” A copy of the press release is furnished as Exhibit 99.1. The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “file…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PEPG PepGen Inc | — | — | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Ensure sufficient cash to fund operations through the second half of 2027.
Stated in 3 of last 3 quarters. Despite negative cash from operations of $18.4M in 2026-Q1, management maintains a strong cash runway into 2H 2027. The recurring focus on cash runway suggests persistent emphasis, but financials show limited progress in reducing cash burn.
“Strong cash runway into 2H 2027, through FREEDOM2 12.5 mg/kg MAD readout.”
“Cash runway into 2H 2027.”
“Company on track to report clinical data... with sufficient cash expected to fund operations into 2H 2027.”
Deliver clinical data from the FREEDOM2 10 mg/kg multiple dose cohort in the second half of 2026.
Stated in 2 of last 2 quarters. Management has reiterated the goal of reporting FREEDOM2 10 mg/kg clinical results in 2H 2026. The focus remains consistent, but no specific progress updates or milestones have been disclosed in the financials.
“2H 2026: FREEDOM2 10 mg/kg clinical results.”
“PepGen reiterates guidance for reporting data from the 10 mg/kg cohort in 2H 2026.”
Plan to deliver clinical data from the FREEDOM2 12.5 mg/kg cohort in 2027.
Newly stated in 2026-Q1. Management has announced plans to report FREEDOM2 12.5 mg/kg clinical results in 2027. This is a new priority with no prior financial or operational updates to assess progress.
“2027: FREEDOM2 12.5 mg/kg clinical results.”
Results of Operations and Financial Condition. On March 4, 2026, PepGen Inc. (the "Company") announced its financial results for the year ended December 31, 2025 and issued a press release titled "PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights". A copy of the press release is furnished as Exhibit 99.1. The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “filed” for purpose…
of this Form 8-K shall be deemed to be furnished and not filed: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on November 12, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: November 12, 2025 By: /s/ Noel Donnelly Noel Donnelly,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Repricing of Underwater Options On November 4, 2025, the Board of Directors (the “Board”) of PepGen Inc. (the “Company”) approved an option repricing (the “Repricing”), effective as of November 4, 2025 (the “Effective Date”). The Repricing was undertaken in accordance with, and as permitted by, the Company’s 2020 Stock Plan (the “2020 Plan”), 2…
Entry into a Material Definitive Agreement. On September 24, 2025, PepGen Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as joint book-running managers (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 31,250,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of…